JP2025504496A5 - - Google Patents

Info

Publication number
JP2025504496A5
JP2025504496A5 JP2024543357A JP2024543357A JP2025504496A5 JP 2025504496 A5 JP2025504496 A5 JP 2025504496A5 JP 2024543357 A JP2024543357 A JP 2024543357A JP 2024543357 A JP2024543357 A JP 2024543357A JP 2025504496 A5 JP2025504496 A5 JP 2025504496A5
Authority
JP
Japan
Prior art keywords
sequence
sequence shown
variable region
chain variable
sequence number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2024543357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504496A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/072527 external-priority patent/WO2023143227A1/zh
Publication of JP2025504496A publication Critical patent/JP2025504496A/ja
Publication of JP2025504496A5 publication Critical patent/JP2025504496A5/ja
Abandoned legal-status Critical Current

Links

JP2024543357A 2022-01-25 2023-01-17 抗ｃｄ７３抗体及び使用 Abandoned JP2025504496A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210098976.1 2022-01-25
CN202210098976 2022-01-25
PCT/CN2023/072527 WO2023143227A1 (zh) 2022-01-25 2023-01-17 抗cd73抗体及应用

Publications (2)

Publication Number Publication Date
JP2025504496A JP2025504496A (ja) 2025-02-12
JP2025504496A5 true JP2025504496A5 (https=) 2026-01-06

Family

ID=87470540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543357A Abandoned JP2025504496A (ja) 2022-01-25 2023-01-17 抗ｃｄ７３抗体及び使用

Country Status (6)

Country Link
EP (1) EP4471062A4 (https=)
JP (1) JP2025504496A (https=)
KR (1) KR20240139053A (https=)
CN (1) CN118591559A (https=)
AU (1) AU2023212216A1 (https=)
WO (1) WO2023143227A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119744177A (zh) * 2023-07-24 2025-04-01 石药集团巨石生物制药有限公司 重组人源化抗cd73单克隆抗体的药物组合物
WO2025125545A1 (en) * 2023-12-15 2025-06-19 Sanofi Effectorless igg1 fc variants

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2537445A (en) 2014-11-10 2016-10-19 Medimmune Ltd Binding molecules specific for CD73 and uses thereof
AU2015349878A1 (en) * 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
EP3423494A1 (en) * 2016-03-04 2019-01-09 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
EP3569618A1 (en) * 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody

Similar Documents

Publication Publication Date Title
JP2023504003A5 (https=)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2025102836A5 (https=)
IL293241A (en) Bispecific antibody, anti-1-pd, anti-vegfa, pharmaceutical preparation containing it and its use
JP2022515318A5 (https=)
JP2021524249A5 (https=)
JP2021525082A5 (https=)
JP2020501531A5 (https=)
JP2019500892A5 (https=)
RU2017145150A (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
JP2020534351A5 (https=)
JP2022525071A5 (https=)
JP2026041845A5 (https=)
JP2023543152A5 (https=)
JP2024509018A5 (https=)
JP2022512642A5 (https=)
JP2025504496A5 (https=)
JP2023518153A5 (https=)
JP2024538669A5 (https=)
JP2024540148A5 (https=)
JP2024515396A5 (https=)
JP2025507817A5 (https=)
JP2021515542A5 (https=)
JP2024525916A5 (https=)
JP2023517754A5 (https=)